There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW – Research Report) and Mesoblast Limited (MEOBF – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edwards Lifesciences (EW)
In a report released today, Adam Maeder from Piper Sandler reiterated a Buy rating on Edwards Lifesciences, with a price target of $90.00. The company’s shares closed last Tuesday at $77.01.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $88.92 average price target, implying a 14.2% upside from current levels. In a report issued on September 30, TR | OpenAI – 4o also upgraded the stock to Buy with a $86.00 price target.
See the top stocks recommended by analysts >>
Mesoblast Limited (MEOBF)
Canaccord Genuity analyst Elyse Shapiro maintained a Buy rating on Mesoblast Limited today and set a price target of A$3.11. The company’s shares closed last Tuesday at $1.90.
According to TipRanks.com, Shapiro is ranked 0 out of 5 stars with an average return of
Mesoblast Limited has an analyst consensus of Moderate Buy, with a price target consensus of $2.03.
Read More on EW:
Disclaimer & DisclosureReport an Issue
- Netflix upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Outperform from In Line at Evercore ISI
- Edwards Lifesciences price target lowered to $85 from $95 at Stifel
- Edwards Lifesciences management to meet with Piper Sandler
- Edwards Lifesciences: Strategic Positioning and Growth Potential Drive Buy Rating Amid TAVR Market Expansion